Anxiety Disorders
Recent clinical, regulatory, research and industry developments relating to this disease.
Central Precocious Puberty and Psychiatric Disorders.
LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up.
Substance P's Impact on Chronic Pain and Psychiatric Conditions-A Narrative Review.
Implications of Online Self-Diagnosis in Psychiatry.
Psychedelic-assisted therapy for people with gambling disorder?
Understanding the heterogeneity of anxiety using a translational neuroscience approach.
Determinants and Outcomes of Suicidal Behavior Among Patients With Major Depressive Disorder.
Psychiatric Disorders Before and After Dementia Diagnosis.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q4 2026.
- Q4 2026Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia：A Prospective, Double-Blind, Randomized, Placebo-Controlled Clinical Trial
- Q2 2027Phase III, Randomized, Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device With Conventional Drug Treatment, Compared to Conventional Drug Treatment Alone, in Adult Patients With Moderate to Severe Generalized Anxiety Disorder
- Q3 2027Cannabidiol-Enhanced Cognitive Behavioral Therapy for Generalized Anxiety Disorder
- Q4 2027Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
Clinical MilestonesView all 10Hide
- 2026-04-01Phase III, Randomized, Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device With Conventional Drug Treatment, Compared to Conventional Drug Treatment Alone, in Adult Patients With Moderate to Severe Generalized Anxiety DisorderResults expected Q2 2027
- 2026-03-09Cannabidiol-Enhanced Cognitive Behavioral Therapy for Generalized Anxiety DisorderResults expected Q3 2027
- 2026-01-05Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia：A Prospective, Double-Blind, Randomized, Placebo-Controlled Clinical TrialResults expected Q4 2026
- 2025-10-31Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and DepressionResults expected Q4 2027
- 2026-06-30Safety and Efficacy of Buagafuran Capsules in the Treatment of Generalized Anxiety Disorder: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Flexible-dose Phase Ⅲ Clinical TrialPrimary completion
- 2026-04-29A Phase 3b, Randomized, Double-blind, 8-week, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Centanafadine Once Daily Extended-release Capsules for the Treatment of Adults With Attention-deficit/Hyperactivity Disorder and Comorbid AnxietyCompleted
- 2025-11-01Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion. A Randomized Double-blind Controlled Trial.Completed
- 2025-09-26A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety DisorderCompleted
- 2025-08-29The Efficacy of Melatonin Patches on Dental Anxiety in Children A Randomized Clinical TrialCompleted
- 2026-06-30ClinicalSafety and Efficacy of Buagafuran Capsules in the Treatment of Generalized Anxiety Disorder: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Flexible-dose Phase Ⅲ Clinical TrialPrimary completion
- 2026-05-19ClinicalA Phase 3, Randomized, Double-blind, 2-arm, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of BNC210 for the Acute, As-needed Treatment of Anxiety in Adults With Social Anxiety DisorderResults posted
- 2026-04-29ClinicalA Phase 3b, Randomized, Double-blind, 8-week, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Centanafadine Once Daily Extended-release Capsules for the Treatment of Adults With Attention-deficit/Hyperactivity Disorder and Comorbid AnxietyCompleted
- 2026-04-01ClinicalPhase III, Randomized, Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device With Conventional Drug Treatment, Compared to Conventional Drug Treatment Alone, in Adult Patients With Moderate to Severe Generalized Anxiety DisorderResults expected Q2 2027
- 2026-03-09ClinicalCannabidiol-Enhanced Cognitive Behavioral Therapy for Generalized Anxiety DisorderResults expected Q3 2027
- 2026-01-05ClinicalEfficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia：A Prospective, Double-Blind, Randomized, Placebo-Controlled Clinical TrialResults expected Q4 2026
- 2025-11-01ClinicalImpact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion. A Randomized Double-blind Controlled Trial.Completed
- 2025-10-31ClinicalProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and DepressionResults expected Q4 2027
- 2025-09-26ClinicalA Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety DisorderCompleted
- 2025-08-29ClinicalThe Efficacy of Melatonin Patches on Dental Anxiety in Children A Randomized Clinical TrialCompleted
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Hallucinogens8
- Anxiety5
- Anxiety Disorders5
- Major Depressive Disorder5
- Mental Disorders5
- Psychiatry5
- Attention Deficit Disorder with Hyperactivity4
- Substance-Related Disorders4
Leading journals6
- JAMA network open5
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2
- Acta dermato-venereologica1
- Acta psychiatrica Scandinavica1
- American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics1
- Animal models and experimental medicine1
Leading researchers8
- Demetrovics Z2
- Shi Y2
- Zhang J2
- Abbott MW1
- Abd-Alrazaq A1
- Abrol E1
- Achtyes ED1
- Agyapong B1
Affiliations (unnormalised)6
- Karolinska Institutet2
- New York University2
- University College London2
- 1Centre of Excellence in Responsible Gaming1
- 2Institute of Psychology1
- 3Amsterdam University Medical Centers1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Anxiety disorders are persistent and disabling conditions characterized by ongoing anxiety. The supplied literature frames them as a major contributor to global mental health burden and as a topic studied across epidemiology, psychology, genetics, and physiopathology.
The grounding supports a multifactorial aetiology rather than a single cause. It specifically notes associations with inflammation and peripheral inflammatory cytokines in generalized anxiety disorder, and it also places anxiety disorders within broader psychiatric and psychological contexts.
The literature links anxiety disorders to physiopathology involving inflammatory signaling and to psychological processes such as fear, adaptation, and psychopathology. A review of psychedelic-induced neuroplasticity also suggests that changes in neuroplasticity-related genes and processes may be relevant to anxiety-related symptom improvement, although this is presented as a therapeutic mechanism rather than a disease mechanism.
The supplied material identifies COVID-19 as an environmental context that exacerbated determinants of poor mental health and increased the prevalence and burden of anxiety disorders. It also notes stress and burnout as correlates of anxiety in teachers, and the broader literature includes risk-related and suicidal-ideation-related themes.
The grounding supports drug therapy as a treatment modality but does not provide a full standard regimen. It specifically includes serotonergic psychedelics such as psilocybin and lysergic acid diethylamide in modern clinical studies of mental health conditions, indicating that psychedelic-assisted therapy has been investigated for anxiety-related symptoms. Beyond that, the supplied material does not support a more specific treatment standard.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Persistent and disabling ANXIETY.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.